ClinicalTrials.gg
WithdrawnNCT05263739Updated Sep 12, 2025

A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies

A Phase 1 interventional study of ESG206 in B-cell Lymphoid Malignancies, sponsored by Shanghai Escugen Biotechnology Co., Ltd. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Sponsored by Shanghai Escugen Biotechnology Co., Ltd · Phase 1, Interventional, and Treatment

Why this study was withdrawn
Due to the company's development strategy adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The purpose is to evaluate the clinical safety, tolerability, PK, and preliminary efficacy and to establish the MTD, if any, and RP2D(s) of ESG206 in adult subjects with B lymphoid malignancies.

Read the detailed description

This is a first-in-human phase I, multicenter, open label, sequential-cohort, dose escalation study of ESG206. The study will follow a modified 3+3 dose escalation scheme. Dose escalation will continue until identification of MTD or the predicted efficacy dose in the event that a MTD is not identified due to paucity of DLTs. Toxicity including dose-limiting toxicity (DLT) observed in Cycle 1 of the first 28 days will be used to determine escalation to the next dose level as described below.

Five dose levels are planned. Dose choosing will be determined by the SMC and the sponsor based on the pharmacokinetics, tolerability and preliminary antitumor activities, as well as other available data.

Subjects will be monitored for safety, tolerability, and efficacy throughout the study.

02

Conditions studied

  • B-cell Lymphoid Malignancies
03

In context

Lead sponsor

Shanghai Escugen Biotechnology Co., Ltd is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written for the trial.
  • Male or female and at least 18 years of age.
  • Subjects must have a confirmed (or documented), incurable B-cell hematologic that had progressed despite standard of care therapy and for which there was no alternative therapy of proven benefit or no effective standard therapy is available or tolerable.
  • Measurable or evaluable Disease.
  • (ECOG) performance status of 0 or 1.
  • Subject must have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has had prior chemotherapy, targeted therapy, immunotherapy or any other agents used as systemic treatment for cancer, within 14 days before first dosing.
  • Had major surgery within 4 weeks before first dosing.
  • Had undergone an stem cell transplant within 100 days before first dosing.
  • Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, or renal disease).
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to the product or .
  • Pregnant or breastfeeding women.
  • Unwillingness or inability to follow the procedures outlined in the protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    ESG206 dose level 1

    ESG206 will be administered intravenously at dose level 1 every two weeks in a 28-day cycle.

    Drug: ESG206

  • Experimental
    ESG206 dose level 2

    ESG206 will be administered intravenously at dose level 2 every two weeks in a 28-day cycle.

    Drug: ESG206

  • Experimental
    ESG206 dose level 3

    ESG206 will be administered intravenously at dose level 3 every two weeks in a 28-day cycle.

    Drug: ESG206

  • Experimental
    ESG206 dose level 4

    ESG206 will be administered intravenously at dose level 4 every two weeks in a 28-day cycle.

    Drug: ESG206

  • Experimental
    ESG206 dose level 5

    ESG206 will be administered intravenously at dose level 5 every two weeks in a 28-day cycle.

    Drug: ESG206

Interventions

  • DrugESG206

    Administered via intravenous (IV) infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Any Treatment Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were defined as: Any AE that happens after treatment initiation,.or AE that was present at time of treatment initiation but worsened after treatment initiation, or AE that was present and resolved prior to treatment and reappeared after treatment initiation after the start of study drug through 30 days after the last dose of study drug. The severity was graded based on the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: First dose date up to last dose plus 30 days

Secondary outcomes

  1. Cmax

    Maximum observed plasma concentration

    Time frame: Up to 20 months

  2. AUC0-inf

    Area under the serum concentration time curve from time 0 extrapolated to infinity

    Time frame: Up to 20 months

  3. Tmax

    Time to maximum plasma concentration

    Time frame: Up to 20 months

  4. T1/2

    Half-life

    Time frame: Up to 20 months

  5. Overall Response (OR)

    Defined as complete response (CR) + partial response (PR)

    Time frame: Up to 20 months

  6. Progression-free Survival (PFS)

    Defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression or death from any cause

    Time frame: Up to 20 months

  7. ADA

    Incidence of anti-drug antibodies

    Time frame: Up to 20 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Aug 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 3, 2022
StartEst.
Dec 2025
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05263739
Lead sponsor
Shanghai Escugen Biotechnology Co., Ltd
Collaborators
Escugen (Australia) Biotechnology Pty Ltd
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Dec 2025 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 12, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-BAFFR Monoclonal Antibody ESG206

Start the discussion